PPV immunotherapy was conducted for patients with mUTUC refractory to the standard chemotherapy. Eligible patients were human leukocyte antigen (HLA) A02, A24, A26, or A03 superfamily positive. A maximum of four HLAmatched peptides was selected based on the preexisting immunoglobulin G (IgG) responses against the 31 warehouse peptides and administered every 1 to 2 week. The overall survival (OS) time was estimated by the Kaplan-Meier method. Association between prevaccination biomarkers, including immune responses, and OS were evaluated by univariate and multivariate analyses with the Cox regression model, and by the Kaplan-Meier method with the logrank test.
INTRODUCTION AND OBJECTIVES: Upper tract urothelial carcinoma (UTUC) show heterogeneous outcome after nephroureterectomy (NU). Despite gender-specific differences, no comparative studies exist for this tumor. The aim of this investigation was to describe tumor characteristics, and survival in patients with UTUC in a multicenter-based cohort, with special reference to gender-related differences.
METHODS: Cancer-specific survival (CSS) of 1304 UTUC patients without neoadjuvant chemotherapy staged any pT, pN0-1, M0 after NU were analyzed in a retrospective multicenter study. Median follow-up period was 34 months. The influence of different clinical and histopathologic variables on CSS was determined through uni-and multi-variate Cox regression analyses.
RESULTS: In total, 916 (70.2%) patients were male and 388 (29.8%) were female. Compared to men, women were more likely to have advanced tumor stages (p ¼ 0.007), higher grade (p < 0.001) and lympho-vascular invasion (LVI) (p < 0.001). There was statistical difference in disease recurrence and cancer-specific survival between both genders when analyzed as a group. In LVI status-adjusted analyses, women without LVI were more likely to die of UTUC compared to the male counterparts (p ¼ 0.011). Logistic regression modeling, female gender (HR ¼ 1.42, p ¼ 0.037), LVI (HR ¼ 1.61, p ¼ 0.004), and ECOG performance status (HR ¼ 1.47, p ¼ 0.007) significantly worsened cancer specific deaths. In gender-specific multivariable analyses that adjusted for standard clinico-pathologic features, positive urine cytology at diagnosis (p ¼ 0.001), tumor grade (p ¼ 0.007), LVI (p ¼ 0.005), and pathologic tumor stage (p < 0.001) were independent predictors for CSS.
CONCLUSIONS: In this multicenter-based cohort, female gender was associated with inferior cancer-specific and relative survival. Women present with more aggressive tumor biologic features at NU, this translated into inferior outcomes compared to men in LVIspecific analyses in our cohort. Positive urine cytology at diagnosis, tumor grade, LVI, and pathologic tumor stage, were the factors influencing the course of disease in both genders.
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MP78-08 IMPROVED SURVIVAL OF CYTOREDUCTIVE SURGERY IN ADDITION TO CHEMOTHERAPY FOR METASTATIC UPPER TRACT UROTHELIAL CARCINOMA: RESULTS FROM THE NATIONAL CANCER DATA BASE
Leilei Xia*, Benjamin Taylor, Jose Pulido, Jeremy Bonzo, Thomas Guzzo, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Prior studies have shown a possible survival benefit of cytoreductive surgery (CS) in addition to the standard of care for the treatment of major metastatic urologic cancers, including renal cell carcinoma, prostate cancer, and bladder cancer. The objective of our study was to compare the survival outcomes of chemotherapy combined with CS (nephroureterectomy, nephrectomy, and/or ureterectomy) versus chemotherapy alone for the treatment of metastatic upper tract urothelial carcinoma (mUTUC).
METHODS: We identified patients who presented with mUTUC at diagnosis in the National Cancer Data Base (NCDB) from 2004 to 2014. Only patients who had multi-agent systemic chemotherapy with or without CS were included. Multivariable logistic regression was performed to identify the predictors of receiving CS. Kaplan-Meier survival, log-rank test, and multivariable Cox regression controlled for demographics, socioeconomic factors, and tumor characteristics were used to compare the overall survival (OS) between CS and no CS groups.
RESULTS: We included 657 patients in our study of which 202 (30.75%) underwent CS. Logistic regression showed that patients who were older (OR ¼ 0.98, 95% CI ¼ 0.96-1.00, P ¼0.038), diagnosed with ureteral cancer (OR ¼ 0.42, 95% CI ¼ 0.27-0.66, P < 0.001), and had cN+ disease (OR ¼ 0.33, 95% CI ¼ 0.21-0.54, P < 0.001) were less likely to receive CS. Patients who were treated at a community hospital (OR ¼ 1.96, 95% CI ¼ 1.35-2.86, P < 0.001) were more likely to receive CS. No difference was found in Charlson comorbidity index between the CS and no CS groups (P ¼ 0.434). CS group had significantly higher median OS than no CS group (13.4 vs. 10.3 months, log-rank test P < 0.001, Figure 1 ). Cox regression showed that compared with chemotherapy alone, chemotherapy combined with CS was significantly associated with improved OS (HR ¼ 0.57, 95%CI ¼ 0.44-0.74, P < 0.001).
CONCLUSIONS: Consistent with various other malignancies, CS appears to provide a survival benefit for mUTUC. However, our study is limited by the observational study design. Studies with higher level of evidence, especially randomized controlled trials are needed to validate the findings and to better identify the patients who are most likely to benefit from CS. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1033
Source 
INTRODUCTION AND OBJECTIVES:
A preoperative nomogram to predict complications following radical nephroureterectomy (RNU) has previously been created. This nomogram incorporated 5 variables (patient age, race, ECOG performance status, CKD stage, and Charlson Comorbidity Index [CCI]) with an area under the curve of 72%. We externally validate this nomogram with a distinct international RNU patient population.
METHODS: Amongst 610 RNU patients treated at 7 academic medical centers between 2005 and 2015, 382 (63%) had complete data with all variables reported as the initial nomogram. Logistic regression determined the association between preoperative variables and post-RNU complications. Nomogram validation was performed by analyzing the area under the receiver operating characteristics (AUC-ROC) curve. A calibration plot compared the nomogram-predicted probability of complications with the observed rate of complications within 30 days.
RESULTS: 225 men and 157 women with a median age of 71 were included. 85% of the patients were Caucasian, 18% has an ECOG 2, 25% had a CCI score >5 and 52% had baseline chronic kidney disease (CKD) stage III. Overall, 93 patients (24%) experienced a complication, including 31 (8%) with Clavien grade III. The performance of the nomogram was evaluated using two methods. Discrimination between individual patients was assessed by analyzing the AUC-ROC curve, which was 67.0% (95% CI 60.3%-73.7%). ( Figure  1) A calibration plot compared the performance of the ideal nomogram (indicated by the dotted line), whereas the solid line represents the performance of this specific nomogram. There was a slight underestimation of complications for patients with high nomogram-predicted probabilities. (Figure 2) CONCLUSIONS: External validation of a preoperative RNU complications nomogram noted an AUC-ROC curve of 67% with underestimation of complications for higher predicted probabilities. These observations may be a result of a lower complication rate observed in the validation versus original cohort (24% vs. 38%).
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